Printed from Voxsanity (voxsanity.com.au) — NCT06326021 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Leukaemia
Phase 1 Leukaemia Trial, Recruiting
NCT06326021
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with acute myeloid leukemia (a type of blood cancer) that has not responded to initial treatment, has come back after chemotherapy, has spread outside the bone marrow, has not fully cleared after treatment, or has returned after a bone marrow/stem cell transplant
- People aged between 1 and 70 years old
- People with no history of severe allergic reactions
- People who are reasonably physically well and able to carry out daily activities (as measured by a standard medical scoring system, with a score of 0–2 out of 4)
- People whose cancer cells carry a specific protein on their surface called CD33, confirmed by laboratory testing of bone marrow, cerebrospinal fluid, or tumour tissue
- People whose doctors estimate they are likely to survive at least 60 days
- People (or their legal guardians) who are willing and able to give written consent to participate — guardians must sign for children aged 1–7; both the child and guardian must sign for children aged 8–18; individuals aged 19–70 must sign for themselves
- People for whom a suitable bone marrow/stem cell donor is available, and for whom a stem cell transplant can be carried out after receiving this treatment
Who may not be able to join:
- People with a high level of cancer cells in the blood (above 30%), including those who have previously had a stem cell transplant but whose original donor's blood cells are no longer available for use in making the treatment
- People with increased pressure in the brain or reduced consciousness
- People with significant heart failure or a serious irregular heartbeat
- People with serious breathing or lung problems
- People who have another type of cancer in addition to the blood cancer
- People with a blood clotting disorder called diffuse intravascular coagulation
- People with kidney function test results that are 1.5 times or more above the normal range
- People with sepsis (a serious whole-body infection) or another infection that cannot be controlled
- People with diabetes that cannot be adequately controlled
- People with serious mental health conditions
- People who have significant abnormalities found on a brain MRI scan
- People who have had a previous organ transplant (not including bone marrow or stem cell transplants)
- Women of childbearing age who have a positive pregnancy blood test
- People who test positive for hepatitis B, hepatitis C, HIV/AIDS, or syphilis
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Phone: 86+ 18831006667
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 1
Sponsor
Beijing GoBroad Hospital
Registry
ClinicalTrials.gov
Start date
2 April 2024
Est. completion
15 June 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
Dose-limiting toxicity(DLT); Adverse events (AEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.